Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The company ...

GIFT Nifty ended 22 points or 0.08% down at 25,984.50 indicating a negative opening for domestic indices NSE Nifty 50 and BSE ...

Mankind Pharma's Q1 profit surged 10% YoY to ₹543 crore; brokerage Motilal Oswal expects 14% earnings CAGR over FY24-26 ...

Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial ...

The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced ...

Mankind Pharma will issue non-convertible debentures (NCDs) and commercial papers (CP) worth ₹5,000 crore. These funds will ...

Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The board ...

The company will raise up to Rs 5,000 crore through non-convertible debentures (NCDs) maturing in up to 48 months, according ...

Mankind Pharma Limited’s Fund Raising Committee has finalised a comprehensive plan to issue non-convertible debentures (NCDs) and commercial papers (CP) to raise a total of Rs 5,000 crore on Monday.

Mankind Pharma Ltd.’s board approved issuing Non-Convertible Debentures and Commercial Papers to raise up to ₹10,000 Crore, ...

Mankind Pharma Limited announced today its plans to raise up to ₹100,000 crore through the issuance of non-convertible ...

Mankind Pharma has been in focus since the company announced the acquisition of Bharat Serums and Vaccines from Advent ...